Skip to main content

Table 3 Analysis of prognostic factors for survival

From: Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis

  N Median survival (month; 95% CI) p values
Gender 0.13
 Male 59 11.0 (7.6–14.4)  
 Female 11 8.0 (1.5–14.5)  
Age, y 0.033
 <50 22 17.0 (17.0–17.0)  
 ≥ 50 48 8.0 (6.3–9.7)  
AFP, ng/L 0.438
 ≤ 20 14 8.0 (2.9–13.1)  
 21–399 18 14.0 (11.9–16.1)  
 ≥ 400 38 8.0 (5.6–10.4)  
Additional treatment after RT 0.00
 SBRT alone 20 3.0 (1.1–4.9)  
 SBRT+TACE 46 12.0 (8.9–15.1)  
Radiation Dose 0.376
 ≤ 27.5Gy 4 3.0 (0–8.9)  
 30-35Gy 25 8.0 (6.8–9.2)  
 ≥ 40Gy 41 11.0 (7.7–14.3)  
Origination of PVTT 0.079
 Right branch 49 8.0 (5.8–10.2)  
 Left branch 21 13.0 (8.5–17.5)  
Type of tumor thrombosis 0.107
 Type II 42 8.0 (5.5–10.5)  
 Type III 27 14.0 (8.6–19.4)  
Response (3 m after SBRT) 0.000
 CR 6 *  
 PR 43 13.0 (10.0–16.0)  
 SD 4 **  
 PD 9 4.0 (1.1–6.9)  
  1. Abbreviations: SBRT Stereotactic body radiotherapy, AFP Alpha-fetoprotein, RT Radiotherapy, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease. * The medium survival for patients with CR was not reported because only two patients died in 7th and 11th month. The other four patients were alive, 1 patient with 15 months follow-up, 3 patients with 16 months follow-up after SBRT. ** In the four patients with SD, 3 patients died in the 8th, 8th and 11th month, the other patient was alive with 12 months follow-up